Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection
Approval to dramatically change CAR-T therapies landscape
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Subscribe To Our Newsletter & Stay Updated
